-
Centralized procurement of 44 varieties in the Yangtze River Delta, starting to renew standards Large enterprises still have advantages
Time of Update: 2023-01-05
the drugs In summary, combined with the two national procurement continuation plans in the Yangtze River Delta, the rules are more perfect and the price tends to be more stable.
-
Letter soliciting opinions on the terminology of functional categories of pharmaceutical excipients under the Chinese Pharmacopoeia
Time of Update: 2023-01-05
Letter soliciting opinions on the terminology of functional categories of pharmaceutical excipients under the Chinese Pharmacopoeia Source: National Pharmacopoeia Commission Time: 2022-11-22 20:11:07
-
The four departments announced the third batch of anti-cancer drugs and rare disease drugs subject to the value-added tax policy
Time of Update: 2023-01-05
The Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Medical Products Administration announced in April 2018 that from May 1, 2018, general VAT taxpayers who produce, sell, wholesale, and retail anti-cancer drugs can choose to pay VAT at a rate of 3% according to the simplified method; For imported anti-cancer drugs, import value-added tax will be levied at a reduced rate of 3%.
-
The press conference of the joint prevention and control mechanism of the State Council responded to the focus issue
Time of Update: 2023-01-05
Recently, the comprehensive group of the joint prevention and control mechanism of the State Council has deployed and dispatched all localities to promote the implementation of 20 optimization measures as soon as possible through various methods such as video consultation, scheduling and training.
-
The new use of AstraZeneca old medicine attracts attention! What are the implications of "drug concession investment"?
Time of Update: 2023-01-05
Industry experts pointed out that the advantages of drug delivery and drug release technology accumulated by AstraZeneca for many years of research and development are difficult to be surpassed in a short time, but on the other hand, this "on-demand drug delivery" strategy, which truly takes clinical needs as the innovation goal, is what China's innovative pharmaceutical companies should learn from.
-
Structure determines function, and the key physicochemical properties of adhesives help tablets form perfectly Webinar replay
Time of Update: 2023-01-05
Ashland Pharmaceutical Excipients Webinar· The playback structure determines the function, and the key physical and chemical properties of the adhesive help the tablet to form perfectly Dr. Yi Liu is
-
How are the pharmaceutical companies doing now after those "sending children to fly solo"?
Time of Update: 2023-01-05
Taking MicroPort, which was spun off and listed by a number of subsidiaries, the company achieved revenue of US$405 million in the first half of the year, a year-on-year increase of 5.
-
Announcement on the adjustment of the schedule of the 88th API China and the 26th CHINA-PHARM
Time of Update: 2023-01-05
Dear exhibitors, visitors and industry friends, In view of the recent situation of the national epidemic facing many points, wide areas and frequent occurrences, and the severe and complex prevention
-
The digital and intelligent transformation of the pharmaceutical industry is timely, and pharmaceutical equipment companies are here to help
Time of Update: 2023-01-05
The digital transformation of the pharmaceutical industry is timely In recent years, with the rapid development of new technologies such as digitalization, artificial intelligence, and 5G, it has brought great changes to the traditional manufacturing industry.
-
2023 Shanghai International Medical Equipment Exhibition
Time of Update: 2023-01-05
2023 Shanghai International Medical Equipment ExhibitionChina International Medical Equipment Fair 2023 The Shang Hai interna tional Medical Devices Exhibition Date: June 28-30, 2023 Venue: Shanghai
-
The intensive development of pharmacies has accelerated, and single stores will be eliminated
Time of Update: 2023-01-05
Last year, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the 14th Five-Year Plan" Period (hereinaft
-
High performance - analysis of the situation of some medical device listed companies in the first three quarters
Time of Update: 2023-01-05
According to the statistics of Medical Equipment Data Cloud, as of October 31, a total of 120 listed medical device companies have issued performance reports, and more than 90% of the company's revenue and net profit in the first three quarters have maintained a growth trend.
-
2023 Shanghai Medical Exhibition
Time of Update: 2023-01-05
2023 Shanghai International Medical Equipment Exhibition China International Medical Equipment Fair 2023 The Shang Hai interna tional Medical Devices Exhibition Date: June 28-30, 2023 Venue: Shanghai
-
Recently, a number of domestic new drugs have ushered in clinical trials and good news for marketing
Time of Update: 2023-01-05
In the increasingly crowded R&D track and fiercer market competition, many pharmaceutical companies are accelerating the promotion of scientific and technological innovation and internationalization
-
How do the new regulations on change management during the review of drug registration applications consider to avoid preemptive positions?
Time of Update: 2023-01-05
1 If the matters or contents specified in the original drug registration approval document and its annexes are changed, the applicant shall, in accordance with the provisions and with reference to the relevant technical guidelines, conduct full research and verification of the drug change, fully assess the impact that the change may have on the safety, efficacy and quality controllability of the drug, and submit a supplementary application, filing or report in accordance with the change procedure (Article 11).
-
32 pharmaceutical companies were investigated by institutions, and the stock price of one stock rose 101% in a month
Time of Update: 2023-01-05
According to the data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical APIs. The analysis believes that the recent active performance of the stock is mainly related to its products in cough and fever reducers.
-
The development of the biopharmaceutical industry is favored by policies, which stimulates the acceleration of local innovation of biopharmaceutical consumables and equipment
Time of Update: 2023-01-05
The development of the biomedical industry is accelerating, stimulating local innovation in pharmaceutical equipment (Image source: Pharmaceutical Network) For example, recently, the Shanghai Municipal Science and Technology Commission, the Municipal Economic Information Commission, and the Municipal Health Commission jointly issued the "Shanghai Action Plan for Promoting Cell Therapy Science and Technology Innovation and Industrial Development (2022-2024)".
-
PD-1, CAR-T, rare disease medication... On the eve of the national talks, can the new batch of VAT exemptions accelerate the price reduction of high-priced drugs?
Time of Update: 2023-01-05
The "tax reduction list" of anticancer drugs and rare disease drugs was further expanded In April 2018, the Ministry of Finance and other four departments issued a notice on their official website that in order to encourage the development of the anti-cancer pharmaceutical industry and reduce the cost of drugs for patients, the first batch of anti-cancer drugs in the list will be subject to 3% VAT, and the VAT will be reduced from 13% to 3% for imported drugs.
-
Pharmaceutical biology "absorbs gold" fiercely, with a net purchase of nearly 10.4 billion yuan in financing in November
Time of Update: 2023-01-05
According to statistics, since November, the net purchase of A-share financing has reached more than 28 billion yuan.
According to statistics, since November, the net purchase of A-share financing has reached more than 28 billion yuan.
-
23 pharmaceutical companies surveyed by institutions! Some pharmaceutical companies have received more than 300 institutional attention
Time of Update: 2023-01-05
(Image source: Pharma Network) Judging from the pharmaceutical stocks investigated by institutions in the past 5 days, Gibel has attracted the attention of institutions, with the number of institutional researchers as high as 301, including China Re Asset, CSC, CICC, China Europe Fund, etc.
